224 related articles for article (PubMed ID: 18760506)
1. Long-term proteasome dysfunction in the mouse brain by expression of aberrant ubiquitin.
Fischer DF; van Dijk R; van Tijn P; Hobo B; Verhage MC; van der Schors RC; Li KW; van Minnen J; Hol EM; van Leeuwen FW
Neurobiol Aging; 2009 Jun; 30(6):847-63. PubMed ID: 18760506
[TBL] [Abstract][Full Text] [Related]
2. Low levels of mutant ubiquitin are degraded by the proteasome in vivo.
van Tijn P; Verhage MC; Hobo B; van Leeuwen FW; Fischer DF
J Neurosci Res; 2010 Aug; 88(11):2325-37. PubMed ID: 20336771
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer-associated mutant ubiquitin impairs spatial reference memory.
van Tijn P; Hobo B; Verhage MC; Oitzl MS; van Leeuwen FW; Fischer DF
Physiol Behav; 2011 Feb; 102(2):193-200. PubMed ID: 21059367
[TBL] [Abstract][Full Text] [Related]
4. Global changes to the ubiquitin system in Huntington's disease.
Bennett EJ; Shaler TA; Woodman B; Ryu KY; Zaitseva TS; Becker CH; Bates GP; Schulman H; Kopito RR
Nature; 2007 Aug; 448(7154):704-8. PubMed ID: 17687326
[TBL] [Abstract][Full Text] [Related]
5. Conformational diseases: an umbrella for various neurological disorders with an impaired ubiquitin-proteasome system.
de Pril R; Fischer DF; van Leeuwen FW
Neurobiol Aging; 2006 Apr; 27(4):515-23. PubMed ID: 16226348
[TBL] [Abstract][Full Text] [Related]
6. Protein quality control in Alzheimer's disease by the ubiquitin proteasome system.
de Vrij FM; Fischer DF; van Leeuwen FW; Hol EM
Prog Neurobiol; 2004 Dec; 74(5):249-70. PubMed ID: 15582222
[TBL] [Abstract][Full Text] [Related]
7. Molecular misreading: the occurrence of frameshift proteins in different diseases.
van Leeuwen FW; Kros JM; Kamphorst W; van Schravendijk C; de Vos RA
Biochem Soc Trans; 2006 Nov; 34(Pt 5):738-42. PubMed ID: 17052186
[TBL] [Abstract][Full Text] [Related]
8. The neuronal ubiquitin-proteasome system: murine models and their neurological phenotype.
van Tijn P; Hol EM; van Leeuwen FW; Fischer DF
Prog Neurobiol; 2008 Jun; 85(2):176-93. PubMed ID: 18448229
[TBL] [Abstract][Full Text] [Related]
9. Mutant ubiquitin decreases amyloid β plaque formation in a transgenic mouse model of Alzheimer's disease.
van Tijn P; Dennissen FJ; Gentier RJ; Hobo B; Hermes D; Steinbusch HW; Van Leeuwen FW; Fischer DF
Neurochem Int; 2012 Oct; 61(5):739-48. PubMed ID: 22797007
[TBL] [Abstract][Full Text] [Related]
10. The hAPP-YAC transgenic model has elevated UPS activity in the frontal cortex similar to Alzheimer's disease and Down's syndrome.
Seo H; Isacson O
J Neurochem; 2010 Sep; 114(6):1819-26. PubMed ID: 20698932
[TBL] [Abstract][Full Text] [Related]
11. Long-term proteasomal inhibition in transgenic mice by UBB(+1) expression results in dysfunction of central respiration control reminiscent of brainstem neuropathology in Alzheimer patients.
Irmler M; Gentier RJ; Dennissen FJ; Schulz H; Bolle I; Hölter SM; Kallnik M; Cheng JJ; Klingenspor M; Rozman J; Ehrhardt N; Hermes DJ; Gailus-Durner V; Fuchs H; Hrabě de Angelis M; Meyer HE; Hopkins DA; Van Leeuwen FW; Beckers J
Acta Neuropathol; 2012 Aug; 124(2):187-97. PubMed ID: 22730000
[TBL] [Abstract][Full Text] [Related]
12. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation.
Bowman AB; Yoo SY; Dantuma NP; Zoghbi HY
Hum Mol Genet; 2005 Mar; 14(5):679-91. PubMed ID: 15661755
[TBL] [Abstract][Full Text] [Related]
13. Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain.
Fischer DF; De Vos RA; Van Dijk R; De Vrij FM; Proper EA; Sonnemans MA; Verhage MC; Sluijs JA; Hobo B; Zouambia M; Steur EN; Kamphorst W; Hol EM; Van Leeuwen FW
FASEB J; 2003 Nov; 17(14):2014-24. PubMed ID: 14597671
[TBL] [Abstract][Full Text] [Related]
14. Amyloid peptide attenuates the proteasome activity in neuronal cells.
Oh S; Hong HS; Hwang E; Sim HJ; Lee W; Shin SJ; Mook-Jung I
Mech Ageing Dev; 2005 Dec; 126(12):1292-9. PubMed ID: 16153690
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
Hol EM; Fischer DF; Ovaa H; Scheper W
Expert Rev Neurother; 2006 Sep; 6(9):1337-47. PubMed ID: 17009921
[TBL] [Abstract][Full Text] [Related]
16. Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegenerative disease.
van Tijn P; de Vrij FM; Schuurman KG; Dantuma NP; Fischer DF; van Leeuwen FW; Hol EM
J Cell Sci; 2007 May; 120(Pt 9):1615-23. PubMed ID: 17405812
[TBL] [Abstract][Full Text] [Related]
17. Endoplasmic reticulum stress compromises the ubiquitin-proteasome system.
Menéndez-Benito V; Verhoef LG; Masucci MG; Dantuma NP
Hum Mol Genet; 2005 Oct; 14(19):2787-99. PubMed ID: 16103128
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases.
de Pril R; Fischer DF; Maat-Schieman ML; Hobo B; de Vos RA; Brunt ER; Hol EM; Roos RA; van Leeuwen FW
Hum Mol Genet; 2004 Aug; 13(16):1803-13. PubMed ID: 15198995
[TBL] [Abstract][Full Text] [Related]
19. Limbic structures are prone to age-related impairments in proteasome activity and neuronal ubiquitinated inclusions in SAMP10 mouse: a model of cerebral degeneration.
Shimada A; Keino H; Kawamura N; Chiba Y; Hosokawa M
Neuropathol Appl Neurobiol; 2008 Feb; 34(1):33-51. PubMed ID: 17973906
[TBL] [Abstract][Full Text] [Related]
20. The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B+1.
Hol EM; van Leeuwen FW; Fischer DF
Trends Mol Med; 2005 Nov; 11(11):488-95. PubMed ID: 16213790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
